Who is sponsoring NCT05643118?

NCT05643118 is sponsored by Olix Pharmaceuticals, Inc..

What drugs are being tested in NCT05643118?

Interventions in NCT05643118: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA).

What condition does NCT05643118 study?

NCT05643118 studies Neovascular Age-related Macular Degeneration.

Is NCT05643118 still recruiting?

NCT05643118 is currently completed. Last updated 11 December 2025.

Last reviewed 2025-12-11 · How we verify

NCT05643118

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Completed Phase 1 Last updated 11 December 2025

What this trial tests

Phase 1 trial testing OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA) in Neovascular Age-related Macular Degeneration in 21 participants. Completed in 10 November 2025.

Timeline

4 January 2023

Primary endpoint
25 November 2024

10 November 2025

Quick facts

Lead sponsor	Olix Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	4 January 2023
Primary completion	25 November 2024
Estimated completion	10 November 2025
Sites	5 locations across United States

Drugs / interventions tested

OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)

Conditions studied

Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →

Sponsor

Olix Pharmaceuticals, Inc. — full company profile →

Who can join

50 and older, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, and Part B is a multiple ascending dose study. The primary objective is to evaluate the safety and tolerability of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD. The exploratory objectives are to evaluate the preliminary efficacy of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD, and to evaluate the pharmacokinetics (PK) of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Current Approaches to Epigenetic Therapy.
Griazeva ED, Fedoseeva DM, Radion EI, Ershov PV, et al · · 2023 · cited 11× · PMID 37873808 · DOI 10.3390/epigenomes7040023
Advances in locally administered nucleic acid therapeutics.
Shen J, Duan X, Xie T, Zhang X, et al · · 2025 · cited 5× · PMID 40144794 · DOI 10.1016/j.bioactmat.2025.02.043
Nanomaterial-Based Anti-Angiogenic Gene Therapy for Retinal Neovascular Diseases: Mechanistic Insights and Preclinical Advances.
Zeng L, Wei Y, Qiu Y, Bi R, et al · · 2025 · cited 1× · PMID 40989889 · DOI 10.2147/ijn.s521960
Therapeutic siRNA: Mechanisms, challenges, strategies, and clinical translation.
Jiang Q, Fu J, An Y, Liu Y. · · 2026 · PMID 42036903 · DOI 10.1097/cm9.0000000000004061
Can MicroRNAs serve as reliable biomarkers and novel therapeutic targets in age-related macular degeneration? A systematic review and meta-analysis.
Chen KY, Chan HC, Chan CM. · · 2026 · PMID 41680791 · DOI 10.1186/s12967-025-07593-x

Verify or expand the search:

Other recruiting trials for Neovascular Age-related Macular Degeneration

Currently open trials in the same condition.

NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting

Other Olix Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT04877756 — Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery · Phase 2 · completed
NCT03569267 — A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05643118 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Olix Pharmaceuticals, Inc.
Last refreshed: 11 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05643118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing